These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 6230227)

  • 21. Norfloxacin: activity against urinary tract pathogens and factors influencing the emergence of resistance.
    Greenwood D; Osman M; Goodwin J; Cowlishaw WA; Slack R
    J Antimicrob Chemother; 1984 Apr; 13(4):315-23. PubMed ID: 6233248
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative antimicrobial activity of enoxacin, ciprofloxacin, amifloxacin, norfloxacin and ofloxacin against 177 bacterial isolates.
    Bassey CM; Baltch AL; Smith RP
    J Antimicrob Chemother; 1986 May; 17(5):623-8. PubMed ID: 2941401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Frequency of appearance of resistant variants to norfloxacin and nalidixic acid.
    Duckworth GJ; Williams JD
    J Antimicrob Chemother; 1984 May; 13 Suppl B():33-8. PubMed ID: 6234273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The in-vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid.
    King A; Shannon K; Phillips I
    J Antimicrob Chemother; 1984 Apr; 13(4):325-31. PubMed ID: 6233249
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro effect of pH and glucose concentration on the antibacterial activity of norfloxacin in urine.
    Fromtling RA; Abruzzo GK; Gadebusch HH
    Methods Find Exp Clin Pharmacol; 1984 Dec; 6(12):737-41. PubMed ID: 6241649
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [In vitro activity of seven gyrase inhibitors of a group of heterocyclic carbonic acids against nonfermenting gram negative rods (nonfermenters)].
    Grimm H
    Arzneimittelforschung; 1985; 35(3):570-2. PubMed ID: 2986655
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bactericidal effects of norfloxacin towards bacteria in urine.
    Lacey RW; Lord VL; Howson GL
    J Antimicrob Chemother; 1984 May; 13 Suppl B():49-54. PubMed ID: 6234275
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative in vitro activity of three new quinolone antibiotics against recent clinical isolates.
    Forsgren A
    Scand J Infect Dis; 1985; 17(1):91-4. PubMed ID: 3158070
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid.
    Bauernfeind A; Petermüller C
    Eur J Clin Microbiol; 1983 Apr; 2(2):111-5. PubMed ID: 6222896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rifampicin plus nalidixic acid: a rational combination for the treatment of urinary infection.
    Greenwood D; Andrew J
    J Antimicrob Chemother; 1978 Nov; 4(6):533-8. PubMed ID: 101503
    [No Abstract]   [Full Text] [Related]  

  • 31. Study of the in vitro activity of norfloxacin and other drugs on amoxicillin-resistant uropathogenic isolates.
    Piccolomini R; Allocati N; Catamo G
    Chemioterapia; 1984 Jun; 3(3):167-72. PubMed ID: 6241505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Sensitivity of Pseudomonas aeruginosa strains isolated from pathological fluids to nalidixic acid and some antibacterial agents].
    Vaszary I; Gláz E
    Orv Hetil; 1965 Aug; 106(34):1595-8. PubMed ID: 4953226
    [No Abstract]   [Full Text] [Related]  

  • 33. Comparison of the antibacterial activity of norfloxacin (MK 0366, AM 715), a new organic acid, with that of other orally absorbed chemotherapeutic agents.
    Gadebusch HH; Shungu DL; Weinberg E; Chung SK
    Infection; 1982 Jan; 10(1):41-4. PubMed ID: 6461606
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of norfloxacin on Staphylococcus aureus and Pseudomonas aeruginosa in broth, serum and in combination with human polymorphonuclear leukocytes.
    Daschner F; Bassler M; Bosbach U
    Eur J Clin Microbiol; 1983 Jun; 2(3):274-6. PubMed ID: 6224689
    [No Abstract]   [Full Text] [Related]  

  • 35. Susceptibility of Pseudomonas aeruginosa of various pyocin types to the newly synthesized ampicillin derivative, N-(6,7-difluoroquinolonyl)ampicillin.
    Chen CH; Tsou TL; Chiang HY; Lee SH; Lee F; Lee JH; Wang TM; Liu YT
    J Antimicrob Chemother; 1997 Mar; 39(3):325-30. PubMed ID: 9096181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nalidixic acid and oxolinic acid in the treatment of chronic bacteriuria.
    Atlas E; Clark H; Silverblatt F; Turck M
    Ann Intern Med; 1969 Apr; 70(4):713-21. PubMed ID: 4977045
    [No Abstract]   [Full Text] [Related]  

  • 37. Mutational resistance to 4-quinolone antibacterial agents.
    Smith JT
    Eur J Clin Microbiol; 1984 Aug; 3(4):347-50. PubMed ID: 6237904
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro antibacterial activity of norfloxacin compared with eight other antimicrobial agents.
    Body BA; Fromtling RA; Shadomy S; Shadomy HJ
    Eur J Clin Microbiol; 1983 Jun; 2(3):230-4. PubMed ID: 6224678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investigations into the mechanism of action of the antibacterial agent norfloxacin.
    Crumplin GC; Kenwright M; Hirst T
    J Antimicrob Chemother; 1984 May; 13 Suppl B():9-23. PubMed ID: 6203890
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resistance of Pseudomonas aeruginosa PAO to nalidixic acid and low levels of beta-lactam antibiotics: mapping of chromosomal genes.
    Rella M; Haas D
    Antimicrob Agents Chemother; 1982 Aug; 22(2):242-9. PubMed ID: 6821455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.